Please Wait.....
Report
Brain Tumor Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 114 Pages I Mordor Intelligence
Brain Tumor Therapeutics Market Analysis
The brain tumor therapeutics market reached USD 3.19 billion in 2025 and is forecast to climb to USD 4.67 billion by 2030, expanding at a 7.89% CAGR. Robust growth reflects the convergence of precision-medicine breakthroughs, fast-track approvals, and a steady pipeline of late-stage assets that shorten the bench-to-bedside journey. The commercial roll-out of Boron Neutron Capture Therapy (BNCT) alongside AI-enabled drug-repurposing tools is shifting therapeutic expectations, particularly for glioma and other high-grade tumors. Intravenous regimens still dominate clinical practice because they allow tight pharmacokinetic control, yet oral targeted agents are gaining traction as blood-brain barrier solutions improve. Investors continue to funnel record sums into neuro-oncology, with large biopharma groups allocating more than USD 53 billion to neurological assets in the past two years. However, radio-isotope supply chain disruptions and elevated therapy costs temper near-term momentum.
Global Brain Tumor Therapeutics Market Trends and Insights
Late-stage pipeline expansion & accelerated FDA approvals
Regulatory speed continues to reshape the brain tumor therapeutics market. Vorasidenib's 2024 approval for grade 2 IDH-mutant glioma doubled median progression-free survival versus placebo, validating biomarker-guided development paths. Breakthrough therapy designations are compressing timelines, while investigational device exemptions now cover novel radiotherapy platforms such as Alpha DaRT's radium-224 seeds for recurrent glioblastoma. Collective momentum shortens commercialization cycles and encourages multi-arm master trials that match molecular subsets with targeted agents.
Precision-medicine shift toward biomarker-guided therapies
Routine testing for IDH mutation, MGMT promoter methylation, and 1p/19q codeletion now guides regimen selection in leading centers. Liquid biopsy platforms provide real-time molecular readouts, allowing therapy switches before radiographic progression. Machine-learning algorithms integrating multi-omics profiles already predict immunotherapy responses with 90%+ accuracy, a capability that is refining eligibility criteria for checkpoint blockade.
High cost of novel therapeutics & combination regimens
First-in-class cell and gene therapies often exceed USD 400,000 per course, while multi-agent combinations can add another USD 300,000 annually, straining payer budgets. Health systems now link reimbursement to real-world outcomes, creating coverage delays that limit early adoption in lower-income settings.
Other drivers and restraints analyzed in the detailed report include:
Commercial roll-out of compact BNCT platforms / AI-assisted drug repurposing for orphan brain tumors / Blood-brain barrier limits small-molecule & biologic penetration /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Glioblastoma held 51.23% of brain tumor therapeutics market share in 2024 and is projected to grow at an 8.45% CAGR, sustaining the largest slice of the brain tumor therapeutics market size through 2030. High mortality, limited standard-of-care options, and the emergence of tumor-treating fields help maintain investor focus.
Continued device-drug pairings, peptide vaccines, and IDH-selective inhibitors illustrate capital concentration in this segment. Meningioma follows in value terms thanks to refined radiosurgery protocols, whereas pituitary tumors benefit from novel endocrine modulators that normalize hormone levels more predictably. Pediatric-leaning subtypes such as medulloblastoma and ependymoma now integrate risk-adapted radiotherapy with molecular diagnostics, improving five-year survival yet leaving relapsed disease an urgent research priority.
The Brain Tumor Therapeutics Market Report is Segmented by Type of Brain Cancer (Glioblastoma, Meningioma, and More), Therapy (Chemotherapy, Immunotherapy, Gene & Cell Therapy, and More), Route of Administration (Oral, Intravenous, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).
Geography Analysis
North America maintained 40.34% market share in 2024 and enjoys unrivaled clinical-trial density, genomic testing adoption, and payer mechanisms that expedite new product uptake. The region's large installed base of Gamma Knife and BNCT systems supports combination regimens, and philanthropic funding from the Biden Cancer Moonshot sustains translational research programs.
Europe follows with steady contributions as EMA centralized approvals streamline access across member states, and public-private partnerships co-finance orphan-tumor projects. Germany, France, and Italy collectively host more than 120 ongoing brain tumor interventional studies, while pan-European registries supply real-world evidence to health technology assessment agencies.
Asia-Pacific, the fastest-growing region at 8.54% CAGR, benefits from China's regulatory modernization, where 60+ innovative drugs won clearance under accelerated pathways in 2024. Japan's early BNCT adoption makes the country a regional referral hub, and Australian institutions leverage favorable ethics timelines to recruit international patients. Improving reimbursement frameworks in South Korea and Singapore further broaden patient access to leading-edge regimens.
List of Companies Covered in this Report:
Amgen / AstraZeneca / Bayer / Bristol-Myers Squibb / Eisai / Roche / GlaxoSmithKline / Johnson&Johnson / Merck / Novartis / Pfizer / Novocure Ltd. / Celldex Therapeutic / Kintara Therapeutics / DelMar Pharmaceuticals / Abbvie / Daiichi Sankyo Co., Ltd. / Sumitomo Heavy Industries (BNCT Systems) / Neutron Therapeutics / TAE Life Sciences /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Primary & Metastatic Brain Tumors
4.2.2 Continuous Late-stage Pipeline Expansion & Accelerated FDA Approvals
4.2.3 Precision-medicine Shift Toward Biomarker-guided Therapies
4.2.4 Government-sponsored Brain Cancer Initiatives & Funding Boosts
4.2.5 Boron Neutron Capture Therapy (BNCT) Commercial Roll-out Momentum
4.2.6 AI-enabled Drug-repurposing Accelerating Orphan-tumor Candidates
4.3 Market Restraints
4.3.1 High Cost of Novel Therapeutics & Combination Regimens
4.3.2 Blood-brain Barrier Limits Small-molecule & Biologic Penetration
4.3.3 Tumor Micro-environment-driven Immunotherapy Resistance
4.3.4 Radio-isotope Supply Shortages for BNCT Facilities
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Buyers/Consumers
4.7.2 Bargaining Power of Suppliers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitute Products
4.7.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Type of Brain Cancer
5.1.1 Glioblastoma
5.1.2 Meningioma
5.1.3 Pituitary Tumors
5.1.4 Ependymoma
5.1.5 Medulloblastoma
5.1.6 Other Rare Tumors
5.2 By Therapy
5.2.1 Chemotherapy
5.2.2 Immunotherapy
5.2.3 Gene & Cell Therapy
5.2.4 Targeted Small-Molecule Therapy
5.2.5 Tumor-Treating Fields (TTF) & Electro-therapy
5.2.6 Radiotherapy Adjuncts
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Intravenous
5.3.3 Intrathecal / Intraventricular
5.3.4 Convection-Enhanced Delivery
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 South Korea
5.4.3.5 Australia
5.4.3.6 Rest of Asia-pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Amgen Inc.
6.3.2 AstraZeneca PLC
6.3.3 Bayer AG
6.3.4 Bristol-Myers Squibb Company
6.3.5 Eisai Co., Ltd.
6.3.6 F. Hoffmann-La Roche Ltd
6.3.7 GSK plc
6.3.8 Johnson & Johnson (Janssen)
6.3.9 Merck & Co., Inc.
6.3.10 Novartis AG
6.3.11 Pfizer Inc.
6.3.12 Novocure Ltd.
6.3.13 Celldex Therapeutics
6.3.14 Kintara Therapeutics
6.3.15 DelMar Pharmaceuticals
6.3.16 AbbVie Inc.
6.3.17 Daiichi Sankyo Co., Ltd.
6.3.18 Sumitomo Heavy Industries (BNCT Systems)
6.3.19 Neutron Therapeutics
6.3.20 TAE Life Sciences
7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security